5 research outputs found
Π‘ΡΡΡΠΊΡΡΡΠ° ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π΄Π΅ΡΠ΅ΡΠΌΠΈΠ½Π°Π½Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π² ΡΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΈ: ΡΠΎΠΊΡΡ Π½Π° CYP2C8, PTGS1 ΠΈ PTGS2
The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes.Objective: to analyze the nature of the distribution of CYP2C8*3 (rs10509681), CYP2C8*3 (rs11572080), PTGS1 (rs10306135), PTGS1 (rs12353214) and PTGS2 (rs20417) among residents of the North Caucasus.Patients and methods. The study involved 676 volunteers from Russian, Balkar, Kabardian and Ossetian ethnic groups. Carriage of polymorphic markers CYP2C8, PTGS1 and PTGS2 was determined using real-time polymerase chain reaction.Results and discussion. There were no significant differences between the groups in the rs10509681 and rs11572080 variants of the CYP2C8 gene. In all groups, the carriage of a combination of CYP2C8 and CYP2C9 alleles, encoding the phenotype of normal metabolizers, prevailed with a frequency of about 75% or more. The rs10306135 variant of the PTGS1 gene was found in 5.9% of Russians, 1.1% of Balkars, 5.3% of Kabardians, and 10.6% of Ossetians; variant rs12353214 β in 19.1; 9.4; 10.8 and 9.2%, rs20417 polymorphism of the PTGS2 gene in 0.4; 5; 2.8 and 3.1% respectively.Conclusion. The data obtained can be used to develop a more rational approach to the prescription of NSAIDs, taking into account the genetic characteristics of the local population in ethnic regions.ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΡ
ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² (ΠΠΠΠ) ΠΌΠΎΠΆΠ΅Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΠΎΠΉ ΠΏΡΠΈΡΠΎΠ΄ΠΎΠΉ Π³Π΅Π½ΠΎΠ² CYP2C8, PTGS1 ΠΈ PTGS2.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β Π°Π½Π°Π»ΠΈΠ· Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ° ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ CYP2C8*3 (rs10509681), CYP2C8*3 (rs11572080), PTGS1 (rs10306135), PTGS1 (rs12353214) ΠΈ PTGS2 (rs20417) ΡΡΠ΅Π΄ΠΈ ΠΆΠΈΡΠ΅Π»Π΅ΠΉ Π‘Π΅Π²Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΠ°Π²ΠΊΠ°Π·Π°.ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠ°ΡΡΠ²ΠΎΠ²Π°Π»ΠΈ 676 Π΄ΠΎΠ±ΡΠΎΠ²ΠΎΠ»ΡΡΠ΅Π² ΠΈΠ· ΡΡΡΡΠΊΠΎΠΉ, Π±Π°Π»ΠΊΠ°ΡΡΠΊΠΎΠΉ, ΠΊΠ°Π±Π°ΡΠ΄ΠΈΠ½ΡΠΊΠΎΠΉ ΠΈ ΠΎΡΠ΅ΡΠΈΠ½ΡΠΊΠΎΠΉ ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
Π³ΡΡΠΏΠΏ. ΠΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠ½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² CYP2C8, PTGS1 ΠΈ PTGS2 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΎΡΡ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠ½Π°ΡΠΈΠΌΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ ΠΏΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠ°ΠΌ rs10509681 ΠΈ rs11572080 Π³Π΅Π½Π° CYP2C8 Π½Π΅ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ. ΠΠΎ Π²ΡΠ΅Ρ
Π³ΡΡΠΏΠΏΠ°Ρ
ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π»ΠΎ Π½ΠΎΡΠΈΡΠ΅Π»ΡΡΡΠ²ΠΎ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Π°Π»Π»Π΅Π»Π΅ΠΉ CYP2C8 ΠΈ CYP2C9, ΠΊΠΎΠ΄ΠΈΡΡΡΡΠΈΡ
ΡΠ΅Π½ΠΎΡΠΈΠΏ Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·Π°ΡΠΎΡΠΎΠ² Ρ ΡΠ°ΡΡΠΎΡΠΎΠΉ ΠΎΠΊΠΎΠ»ΠΎ 75% ΠΈ Π±ΠΎΠ»Π΅Π΅. ΠΠ°ΡΠΈΠ°Π½Ρ rs10306135 Π³Π΅Π½Π° PTGS1 Π²ΡΡΠ²Π»Π΅Π½ Ρ 5,9% ΡΡΡΡΠΊΠΈΡ
, 1,1% Π±Π°Π»ΠΊΠ°ΡΡΠ΅Π², 5,3% ΠΊΠ°Π±Π°ΡΠ΄ΠΈΠ½ΡΠ΅Π² ΠΈ 10,6% ΠΎΡΠ΅ΡΠΈΠ½; Π²Π°ΡΠΈΠ°Π½Ρ rs12353214 β Ρ 19,1; 9,4; 10,8 ΠΈ 9,2%, ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ rs20417 Π³Π΅Π½Π° PTGS2 β Ρ 0,4; 5; 2,8 ΠΈ 3,1% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ ΠΏΡΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ΅ Π±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° ΠΊ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΠΠΠ, ΡΡΠΈΡΡΠ²Π°ΡΡΠ΅Π³ΠΎ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π² ΡΡΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅Π³ΠΈΠΎΠ½Π°Ρ
Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis
Aim. To investigate the effect of ABCB1 gene carriage and interdrug interactions on apixaban pharmacokinetics and clinical outcomes in patients with atrial fibrillation and deep vein thrombosis.Material and methods. Patients hospitalized at Yudin State Clinical Hospital participated in the study. A total of 92 patients (50 patients received apixaban and 42 β rivaroxaban) with non-valvular atrial fibrillation and deep vein thrombosis were included. Genotyping was performed by real-time polymerase chain reaction. Direct oral anticoagulants concentrations were measured using an electrospray ionization mass spectrometer in positive ionization mode.Results. In our study we found that in patients carrying the CT+TT ABCB1 (rs4148738) C>T genotype encoding the carrier protein (P-gp), the plasma concentration of rivaroxaban was statistically significantly higher p= 0.026. In addition, we found that patients taking apixaban together with a CYP3A4/P-gp inhibitor were 3.5 times more likely to have hemorrhagic complications than those without inhibitors p = 0.004.Conclusion. Our study revealed that the plasma concentration of rivaroxaban was higher in patients carrying the ABCB1 (rs4148738) C>T polymorphism T allele. And patients taking apixaban together with CYP3A4/P-gp inhibitor had higher risk of hemorrhagic complications in comparison with patients not taking such drugs. Further studies are needed on the influence of pharmacogenetics and pharmacokinetics on the safety and efficacy profile of apixaban and rivaroxaban, taking into account the trend of systemic approach to optimization of anticoagulant therapy of direct oral anticoagulants based on pharmacokinetic, pharmacogenetic biomarkers
Pharmacogenetic Aspects of Postoperative Anesthesia with Ketoprofen in Cardiac Surgery Patients
Aim. Evaluation of the effect of polymorphisms of the CYP2D6, CYP2C8 genes on the efficacy and safety of postoperative analgesia with ketoprofen in patients with coronary artery disease after cardiac surgery.Material and methods. The study included 90 patients with an established diagnosis of coronary artery disease and postoperative period after cardiac surgery. Patients received ketoprofen 100 mg intramuscularly 2 times a day for 5 days. The intensity of pain was rated by Numeric Rating Scale. The severity of dyspepsia was assessed by the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire. DNA was isolated from venous blood using an automated system. Single nucleotide polymorphisms CYP2C8 (C>T) rs11572080, CYP2D6*4 (1846G>A) rs3892097 were determined by the real-time polymerase chain reaction method.Results. In patients with genotypes GA and GG for the allelic variant CYP2D6*4, significant differences in the intensity of pain syndrome were found on days 4 and 5 of the postoperative period: 3,91Β±2,17 and 4,95Β±1,8 points (p=0,04), 3,52Β±1,95 and 4,5Β±1,7 points (p=0,04) in patients with GA and GG genotypes on days 4 and 5, respectively. In patients with the CT genotype for the CYP2C8 rs11572080, the severity of dyspepsia by GSRS was significantly higher than in patients with the CC genotype: 22,67Β±7,64 and 18,97Β±4,25 points, respectively.Conclusion. Patients with the GA genotype for the CYP2D6*4 allelic variant showed a lower intensity of pain syndrome than the GG genotype. In patients with the CT genotype for the CYP2C8 rs11572080, higher dyspepsia was revealed than in the CC genotype
ΠΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° Ρ Π΄Π΅ΡΠ΅ΠΉ Π³ΡΡΠ΄Π½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈΠΈ Π½Π° ΡΠΎΠ½Π΅ Π³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈ-ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π¦ΠΠ‘
Objective: based on the production of cytokines, to identify the immunological features of the chronic course of cytomegalovirus infection in children of the first year of life against the background of hypoxic-ischemic CNS damage.Research methods:108 newborns with cytomegalovirus infection occurring against the background of perinatal hypoxic-ischemic lesions of the central unequal system were examined. All observed patients immediately after the diagnosis of cytomegalovirus infection underwent an immunological examination, including the determination of the levels of interferon-alpha (IFN-Ξ±) and interferon-gamma (IFN-Ξ³), the level of interleukins β 2 and 4 (IL -2 and IL-4) necrosis factor human alpha tumors (TNF-Ξ± in blood serum was determined by enzyme immunoassay using a set of reagents ProCon IF2 plus, ProCon Ifgamma, ProCon TNFΞ± (Protein contour LLC, Russia, St. Petersburg). At 1 and 6 months of life .The observation groups consisted of 78 children (72.2%) with an acute course of the disease (Group 1) and 30 children (27.3%) with a chronic course (Group 2). The control group consisted of 15 newborns without herpes virus infection.Results. Of the totality of the studied cytokines, statistically significant for the chronic course of cytomegalovirus infection in children of the first year of life against the background of hypoxic-ischemic CNS damage were found: IL-2, IFN-Ξ³. It was found that in children with a persistent low level of IFN-Ξ³ and an increased level of IL-4 in the blood serum at the age of 6 months, there was a chronic course of cytomegalovirus infection against the background of perinatal hypoxic-ischemic CNS damage.A decrease in IFN-Ξ³ production indicates a congenital or acquired deficiency of the interferon system and can be considered as an indication for long-term interferon replacement therapy.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΈΠ·ΡΡΠΈΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° ΠΏΡΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠΈ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ, Ρ Π΄Π΅ΡΠ΅ΠΉ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ Π³ΠΎΠ΄Π° ΠΆΠΈΠ·Π½ΠΈ Π½Π° ΡΠΎΠ½Π΅ Π³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈ-ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π¦ΠΠ‘.ΠΠ΅ΡΠΎΠ΄Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ 108 Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΡΡ
Ρ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠ΅ΠΉ, ΠΏΡΠΎΡΠ΅ΠΊΠ°Π²ΡΠ΅ΠΉ Π½Π° ΡΠΎΠ½Π΅ ΠΏΠ΅ΡΠΈΠ½Π°ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈ-ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅ΡΠ°Π²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ. ΠΡΠ΅ΠΌ Π½Π°Π±Π»ΡΠ΄Π°Π²ΡΠΈΠΌΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ ΡΡΠ°Π·Ρ ΠΏΠΎΡΠ»Π΅ ΠΏΠΎΡΡΠ°Π½ΠΎΠ²ΠΊΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΠ·Π° ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½Π°Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ΅Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Π΅ΠΉ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Π°Π»ΡΡΠ° (ΠΠ€Π-Ξ±) ΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Π³Π°ΠΌΠΌΠ° (ΠΠ€Π-Ξ³) ΡΡΠΎΠ²Π΅Π½Ρ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½ΠΎΠ² β 2 ΠΈ 4 (ΠΠ-2 ΠΈ ΠΠ-4), ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ Π°Π»ΡΡΠ° ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (Π€ΠΠ-Ξ±) Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π½Π°Π±ΠΎΡΠ° ΡΠ΅Π°Π³Π΅Π½ΡΠΎΠ² ProConIF2 plus, ProConIfgamma, ProConTNFΞ± (ΠΠΠ Β«ΠΡΠΎΡΠ΅ΠΈΠ½ΠΎΠ²ΡΠΉ ΠΊΠΎΠ½ΡΡΡΒ», Π ΠΎΡΡΠΈΡ, Π³. Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 1 ΠΈ 6 ΠΌΠ΅ΡΡΡΠ΅Π² ΠΆΠΈΠ·Π½ΠΈ. ΠΡΡΠΏΠΏΡ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 78 Π΄Π΅ΡΠ΅ΠΉ (72,2%) Ρ ΠΎΡΡΡΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (1 Π³ΡΡΠΏΠΏΠ°) ΠΈ 30 Π΄Π΅ΡΠ΅ΠΉ (27,3%) Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ (2 Π³ΡΡΠΏΠΏΠ°). ΠΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 15 Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΡΡ
Π±Π΅Π· Π³Π΅ΡΠΏΠ΅ΡΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ· Π²ΡΠ΅ΠΉ ΡΠΎΠ²ΠΎΠΊΡΠΏΠ½ΠΎΡΡΠΈ ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΡ
ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² Π±ΡΠ»ΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ Π΄Π»Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ (Π¦ΠΠΠ) Ρ Π΄Π΅ΡΠ΅ΠΉ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ Π³ΠΎΠ΄Π° ΠΆΠΈΠ·Π½ΠΈ Π½Π° ΡΠΎΠ½Π΅ Π³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈ-ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π¦ΠΠ‘: ΠΠ- 2 ΠΈ ΠΠ€Π-Ξ³. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ ΡΠΎΡ
ΡΠ°Π½ΡΡΡΠΈΠΌΡΡ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΠ€Π-Ξ³ ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΠ-4 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 6 ΠΌΠ΅ΡΡΡΠ΅Π² ΠΈΠΌΠ΅Π»ΠΎ ΠΌΠ΅ΡΡΠΎ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π½Π° ΡΠΎΠ½Π΅ ΠΏΠ΅ΡΠΈΠ½Π°ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π³ΠΈΠΏΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈ-ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π¦ΠΠ‘.Π‘Π½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ ΠΠ€Π-Ξ³, ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π²ΡΠΎΠΆΠ΄ΡΠ½Π½ΠΎΠΌ ΠΈΠ»ΠΈ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΡΠ½Π½ΠΎΠΌ Π΄Π΅ΡΠΈΡΠΈΡΠ΅ ΡΠΈΡΡΠ΅ΠΌΡ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½ΠΎΠ² ΠΈ ΠΌΠΎΠΆΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ ΠΊΠ°ΠΊ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠ΅ Π΄Π»Ρ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π·Π°ΠΌΠ΅ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°ΠΌΠΈ
ΠΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ°ΡΡΡΡ ΠΎΡΡΡΡΡ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π½Π° ΠΏΠ΅ΡΠ²ΠΎΠΌ Π³ΠΎΠ΄Ρ ΠΆΠΈΠ·Π½ΠΈ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ ΡΠ΅ΡΠ΅Π±ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΡΠ΅ΠΌΠΈΠ΅ΠΉ, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΠΎΡΡΠΈ
Objective: to develop prognostic criteria for frequent respiratory diseases in the first year of life in children with cerebral ischemia who had a cytomegalovirus infection in the neonatal period. Research methods: 73 children of the first year of life with cerebral ischemia, who underwent cytomegalovirus infection in the neonatal period, were deployed. All observed patients at the age of three months underwent a study of the population composition of peripheral blood T-lymphocytes using flow cytometry for the expression of membrane markers, taking into account the results on a Beckman Coulter Epics XL II laser flow cytometer. Typing of lymphocytes was carried out using monoclonal antibodies to differentiation clusters CD3+, CD3+CD69+, CD3+CD71+, CD3+CD95+ from Immunotech (France). The observation groups consisted of 30 children (41.1%) with frequent acute respiratory infections (4β5 episodes per year) in the first year of life and 43 people (58.9%) β children with no acute respiratory infectionβsepisodes in the first-year life. Results. From the set of studied T-lymphocytes, statistically significant for the prognosis of frequent acute respiratory infections in the first year of life in children with cerebral ischemia who underwent cytomegalovirus infection in the neonatal period were found: CD3+ CD71+, CD3+ CD95+. It was revealed that in children with a reduced level of CD3+ CD71+ and an increased level of CD3+ CD95+ in blood serum at the age of 3 months, frequent acute respiratory infections occurred in the first year of life.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°ΡΡ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΊΡΠΈΡΠ΅ΡΠΈΠΈ ΡΠ°ΡΡΡΡ
ΠΎΡΡΡΡΡ
ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π½Π° ΠΏΠ΅ΡΠ²ΠΎΠΌ Π³ΠΎΠ΄Ρ ΠΆΠΈΠ·Π½ΠΈ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ ΡΠ΅ΡΠ΅Π±ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΡΠ΅ΠΌΠΈΠ΅ΠΉ, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΠΎΡΡΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ 73 ΡΠ΅Π±Π΅Π½ΠΊΠ° ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ Π³ΠΎΠ΄Π° ΠΆΠΈΠ·Π½ΠΈ Ρ ΡΠ΅ΡΠ΅Π±ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΡΠ΅ΠΌΠΈΠ΅ΠΉ, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΠΎΡΡΠΈ. ΠΡΠ΅ΠΌ Π½Π°Π±Π»ΡΠ΄Π°Π²ΡΠΈΠΌΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΡΡΠ΅Ρ
ΠΌΠ΅ΡΡΡΠ΅Π² ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠΎΡΡΠ°Π²Π° Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΡΠΎΡΠ»ΡΠΎΡΠΈΠΌΠ΅ΡΡΠΈΠΈ ΠΏΠΎ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠ΅ΠΌΠ±ΡΠ°Π½Π½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Ρ ΡΡΠ΅ΡΠΎΠΌ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π½Π° ΠΏΡΠΎΡΠΎΡΠ½ΠΎΠΌ Π»Π°Π·Π΅ΡΠ½ΠΎΠΌ ΡΠΈΡΠΎΡΠ»ΡΠΎΡΠΈΠΌΠ΅ΡΡΠ΅ Beckman Coulter Epics XL II. Π’ΠΈΠΏΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΡ
Π°Π½ΡΠΈΡΠ΅Π» ΠΊ ΠΊΠ»Π°ΡΡΠ΅ΡΠ°ΠΌ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²ΠΊΠΈ Π‘D3+, CD3+ CD69+, CD3+ CD71+, CD3+ CD95+ ΡΠΈΡΠΌΡ Immunotech (Π€ΡΠ°Π½ΡΠΈΡ). ΠΡΡΠΏΠΏΡ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ 30 Π΄Π΅ΡΠ΅ΠΉ (41,1%) Ρ ΡΠ°ΡΡΡΠΌΠΈ ΠΎΡΡΡΡΠΌΠΈ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΠΌ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡΠΌΠΈ (ΠΠ Π) (4β5 ΡΠΏΠΈΠ·ΠΎΠ΄ΠΎΠ² Π² Π³ΠΎΠ΄) Π½Π° ΠΏΠ΅ΡΠ²ΠΎΠΌ Π³ΠΎΠ΄Ρ ΠΆΠΈΠ·Π½ΠΈ ΠΈ 43 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (58,9%) β Π΄Π΅ΡΠΈ Ρ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΡΠΏΠΈΠ·ΠΎΠ΄ΠΎΠ² ΠΠ Π Π½Π° ΠΏΠ΅ΡΠ²ΠΎΠΌ Π³ΠΎΠ΄Ρ ΠΆΠΈΠ·Π½ΠΈ (ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ Π³ΡΡΠΏΠΏΠ°). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ· ΡΠΎΠ²ΠΎΠΊΡΠΏΠ½ΠΎΡΡΠΈ ΠΈΠ·ΡΡΠ°Π΅ΠΌΡΡ
Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π±ΡΠ»ΠΈ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠ΅ Π΄Π»Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΡΠ°ΡΡΡΡ
ΠΎΡΡΡΡΡ
ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π½Π° ΠΏΠ΅ΡΠ²ΠΎΠΌ Π³ΠΎΠ΄Ρ ΠΆΠΈΠ·Π½ΠΈ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ ΡΠ΅ΡΠ΅Π±ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΡΠ΅ΠΌΠΈΠ΅ΠΉ, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΡΠΈΡΠΎΠΌΠ΅Π³Π°Π»ΠΎΠ²ΠΈΡΡΡΠ½ΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ Π½ΠΎΠ²ΠΎΡΠΎΠΆΠ΄Π΅Π½Π½ΠΎΡΡΠΈ: CD3+ CD71+, CD3+ CD95+. ΠΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Ρ Π΄Π΅ΡΠ΅ΠΉ Ρ ΠΏΠΎΠ½ΠΈΠΆΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ CD3+ CD71+ ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ CD3+ CD95+ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ 3-Ρ
ΠΌΠ΅ΡΡΡΠ΅Π² ΠΆΠΈΠ·Π½ΠΈ ΠΈΠΌΠ΅Π»ΠΈ ΠΌΠ΅ΡΡΠΎ ΡΠ°ΡΡΡΠ΅ ΠΎΡΡΡΡΠ΅ ΡΠ΅ΡΠΏΠΈΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π½Π° ΠΏΠ΅ΡΠ²ΠΎΠΌ Π³ΠΎΠ΄Ρ ΠΆΠΈΠ·Π½ΠΈ